Mesoblast Ltd., of Melbourne, Australia, said results of a phase II trial of intravenously delivered mesenchymal precursor cells (MPCs) for the treatment of type 2 diabetes, published in Diabetes Care, showed that a single MPC infusion, ranging from 0.3 to 2 million MPCs/kg, was safe and well tolerated.